Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “ALK-positive Advanced NSCLC Patients”

60 trials

Showing 20 of 60 results

Testing effectiveness (Phase 2)Active Not RecruitingNCT05491811
What this trial is testing

Ensartinib in Combination With Bevacizumab in ALK-positive NSCLC Patients With TP53 Mutation

Who this might be right for
Non-Small Cell Lung Cancer
Sun Yat-sen University 49
Early research (Phase 1)Study completedNCT03607188
What this trial is testing

Study of Alkotinib in Patients With Advanced Non Small Cell Lung Cancer

Who this might be right for
Non-small Cell Lung Cancer
Suzhou Zelgen Biopharmaceuticals Co.,Ltd 17
Not applicableStudy completedNCT03271554
What this trial is testing

Treatment Registry of Alectinib in Anaplastic Lymphoma Kinase (ALK)-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer in Korea

Who this might be right for
Non-Small Cell Lung Cancer
Hoffmann-La Roche 355
Not applicableUnknownNCT04499794
What this trial is testing

The Study of Exosome EML4-ALK Fusion in NSCLC Clinical Diagnosis and Dynamic Monitoring

Who this might be right for
Untreated Advanced NSCLC PatientsFISH Identified ALK Fusion Positive or Negative
Chinese Academy of Medical Sciences 75
Testing effectiveness (Phase 2)Study completedNCT03535740
What this trial is testing

Brigatinib in Participants With Anaplastic Lymphoma Kinase-Positive (ALK+), Advanced Non-Small-Cell Lung Cancer (NSCLC) Progressed on Alectinib or Ceritinib

Who this might be right for
ALK-positive Advanced NSCLC
Ariad Pharmaceuticals 103
Testing effectiveness (Phase 2)WithdrawnNCT01500824
What this trial is testing

A Clinical Study Testing The Safety And Efficacy Of Crizotinib In East Asian Patients With Anaplastic Lymphoma Kinase (ALK) Positive Advanced Non-Small Cell Lung Cancer

Who this might be right for
Non-Small Cell Lung Cancer
Pfizer
Large-scale testing (Phase 3)Active Not RecruitingNCT02838420
What this trial is testing

Evaluate and Compare the Efficacy and Safety of Alectinib Versus Crizotinib and to Evaluate the Pharmacokinetics of Alectinib in Asian Participants With Treatment-Naive Anaplastic Lymphoma Kinase (ALK)-Positive Advanced Non-Small Cell Lung Cancer (NSCLC)

Who this might be right for
Anaplastic Lymphoma Kinase-positive Non-small Cell Lung Cancer
Hoffmann-La Roche 187
Not applicableLooking for participantsNCT06361589
What this trial is testing

Real World Study of Lolatinib for Advanced ALK+ NSCLC Patients

Who this might be right for
ALK-positive Non-small Cell Lung CancerReal World Study
Sichuan Cancer Hospital and Research Institute 200
Not applicableUnknownNCT05132218
What this trial is testing

Ensatinib in alK-positive Patients Undergoing Initial Treatment for Advanced Non-small Cell Lung Cancer

Who this might be right for
ALK PositiveNSCLC Stage IIIBNSCLC Stage IV
Peking University Cancer Hospital & Institute 180
Not applicableNo Longer AvailableNCT03178071
What this trial is testing

Expanded Access For Lorlatinib For Patients With Non Small Cell Lung Cancer ALK Positive or ROS1 Positive

Who this might be right for
Non Small Cell Lung Cancer ALK Positive or ROS1 Positive
Pfizer
Testing effectiveness (Phase 2)Study completedNCT01752400
What this trial is testing

AUY922 for Advanced ALK-positive NSCLC

Who this might be right for
Non Small Cell Lung Cancer
Massachusetts General Hospital 6
Not applicableEnded earlyNCT02228421
What this trial is testing

Study to Evaluate Real-world Pharmacoeconomics of Crizotinib in NSCLC Patients

Who this might be right for
Non-small Cell Lung Cancer Metastatic
PeriPharm 29
Not applicableUnknownNCT02041468
What this trial is testing

Study to Evaluate Resistance Mechanisms and Real-world Pharmacoeconomics of Crizotinib in NSCLC Patients

Who this might be right for
Non-small Cell Lung Cancer Metastatic
Jewish General Hospital 29
Post-approval studies (Phase 4)Study completedNCT04541706
What this trial is testing

Lorlatinib in ALK Inhibitor Treated Unresectable Advanced/Recurrent ALK-Positive Non Small Cell Lung Cancer Patients in India

Who this might be right for
Advanced Non-Small Cell Lung Cancer
Pfizer 100
Early research (Phase 1)Ended earlyNCT03087448
What this trial is testing

Ceritinib + Trametinib in Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer (NSCLC)

Who this might be right for
Non-small Cell Lung Cancer
University of California, San Francisco 9
Large-scale testing (Phase 3)Study completedNCT03596866
What this trial is testing

Brigatinib Compared to Alectinib in Adults With Non-Small-Cell Lung Cancer

Who this might be right for
ALK+ Advanced NSCLC
Takeda 248
Not applicableNot Yet RecruitingNCT07045610
What this trial is testing

Primary Resistance Mechanisms of ALK TKIs

Who this might be right for
ALK-positive Advanced NSCLC PatientsPrimary ResistanceNGS
National Taiwan University Hospital 20
Testing effectiveness (Phase 2)Study completedNCT03779191
What this trial is testing

Alectinib in Combination With Bevacizumab in ALK Positive NSCLC

Who this might be right for
ALK Gene Rearrangement PositiveNon-Squamous Non-Small Cell Neoplasm of Lung
Instituto Nacional de Cancerologia de Mexico 41
Not applicableNot Yet RecruitingNCT07191405
What this trial is testing

Clinical Study of Chemotherapy and Immunotherapy Combined With Lactobacillus Johnsonii in Patients With Multiple Irresectable Solid Tumors

Who this might be right for
ImmunotherapyChemotherapy
Second Affiliated Hospital, School of Medicine, Zhejiang University 156
Testing effectiveness (Phase 2)Study completedNCT04111705
What this trial is testing

Lorlatinib After Failure of First-line Second-generation ALK Kinase Inhibitor in Patients With Advanced ALK-positive Non-small Cell Lung Cancer

Who this might be right for
Non Small Cell Lung Cancer Metastatic
Intergroupe Francophone de Cancerologie Thoracique 23
Load More Results

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation